All News

This interview discusses major themes from OPC 2026, including advances in immunotherapy delivery, practical applications of ASCO and EHA data, and the expanding role of oncology pharmacists in optimizing patient care.

The new indication is for those aged 12 years and older with unresectable or metastatic SS who received prior chemotherapy and are positive for certain genetic subtypes.

This interview discusses common challenges in precision medicine implementation and how oncology pharmacists can build expertise in biomarker interpretation, pharmacogenomics, and multidisciplinary care.

Findings from a retrospective analysis show that montelukast prophylaxis significantly reduced rituximab infusion-related reactions, particularly among patients receiving treatment for oncology indications.

On GLP-1s like semaglutide or tirzepatide, weight loss can mean muscle loss; encourage patients to use protein and resistance training to stay strong.

Pharmacy Times speaks with Caitlin Jones, PHD, on opioids, spinal cord stimulators, and treatment-related harms in chronic low back pain.

Incorporate important health screenings and lifestyle prevention tips in MTM consults.

From AI-driven dispensing to grassroots advocacy wins, here are the key insights Pharmacy Times gathered at McKesson ideaShare 2026 in Denver.

Specialty dispensing and infusion services offer real opportunity—but the path requires careful planning, sequencing, and the right resources.

Emily Flaugher discusses how Health Mart Atlas tools and emerging legislative momentum are helping independent pharmacies navigate reimbursement challenges and unlock new revenue opportunities.

This OPC interview discusses emerging personalized immunotherapy approaches in melanoma, evolving toxicity management strategies, and the future role of cancer vaccines in cutaneous oncology.

Kim Nguyen, PharmD, discusses findings from her OPC abstract on cardiovascular toxicities and drug-drug interactions associated with BTK inhibitors, highlighting strategies for individualized treatment selection and patient monitoring.

Single-cell findings presented at EHA 2026 identify B cells as potential drivers of immune dysregulation in acquired hemophilia A.

Ammoxetine is a novel SNRI derived from duloxetine, exhibiting a 3- to 10-fold greater potency.

Leonard Egede explains why PHQ-9 screening belongs in every cardio-kidney-metabolic (CKM) syndrome risk assessment—and how community pharmacists can reach patients the formal system misses.

Pharmacy streamlines bispecific programs with tailored operations, scheduling, order sets, and reimbursement checkpoints.

The multiple myeloma (MM) approval was based on phase 3 IRAKLIA data demonstrating noninferior efficacy and reduced infusion-related reactions compared with intravenous administration.

Pharmacists cut through probiotic hype by matching strains and doses to evidence, checking shelf-life potency, and navigating confusing regulations.

This abstract was presented at the Oncology Pharmacists Connect (OPC) meeting in Austin, Texas, from June 18 to 19, 2026.

Human connection is often the first casualty of rising prescription counts and constant interruptions.

This abstract was presented at the Oncology Pharmacists Connect (OPC) meeting in Austin, Texas, from June 18 to 19, 2026.

This abstract was presented at the Oncology Pharmacists Connect (OPC) meeting in Austin, Texas, from June 18 to 19, 2026.

This OPC interview discusses the growing importance of molecular testing, care coordination, and oral oncology therapies in optimizing outcomes for patients with gastrointestinal malignancies.

The growing importance of comprehensive biomarker testing, toxicity management, and the expanding role of targeted therapies in early-stage thoracic malignancies.

This abstract was presented at the Oncology Pharmacists Connect (OPC) meeting in Austin, Texas, from June 18 to 19, 2026.

This abstract was presented at the Oncology Pharmacists Connect (OPC) meeting in Austin, Texas, from June 18 to 19, 2026.

Crystal Lennartz, PharmD, MBA, discusses independent pharmacy resilience, recent industry recognitions, and new tools announced at McKesson ideaShare 2026 to support pharmacy growth and transparency.

Leaders of the newly launched Psychedelic Pharmacist Foundation discuss pharmacists' critical role in psychedelic-assisted therapy and patient education.